The T 259 pill is a prescription combination medication containing Hydrocodone Bitartrate (10 mg) and Acetaminophen (325 mg). It is classified as a Schedule II (C-II) controlled substance in the United States and is prescribed for the management of acute or chronic pain severe enough to require an opioid analgesic when alternative treatments are inadequate.
Pill Identification & Physical Characteristics
Attribute – Specification
- Imprint –
T 259 - Active Ingredients – Hydrocodone Bitartrate 10 mg / Acetaminophen 325 mg
- Color – White to off-white
- Shape – Capsule-shaped (oblong)
- Scoring – Bisected (scored on the reverse side)
- Drug Class – Opioid analgesic / Non-opioid analgesic combination
- DEA Schedule – Schedule II (High potential for abuse and dependence)
- Common Generic Equivalents – Generic Norco 10/325, Lortab 10/325, Vicodin HP
Mechanism of Action
The formulation combines two distinct analgesics that work synergistically via central and peripheral pathways:
- Hydrocodone Bitartrate: A semisynthetic opioid agonist that binds primarily to opioid receptors in the central nervous system (CNS). This binding inhibits the release of neurotransmitters involved in pain signaling (such as Substance P) and hyperpolarizes neural pathways, altering the perception and emotional response to pain.
- Acetaminophen (APAP): A non-opioid analgesic and antipyretic. While its exact mechanism remains multifaceted, it acts predominantly centrally by inhibiting prostaglandin synthesis via the cyclooxygenase (COX) pathway and modulating descending serotonergic pathways to elevate the overall pain threshold.
Dosage & Administration
- Typical Adult Dosing: The usual dosage is one tablet every 4 to 6 hours as needed for pain.
- Dosage Titration: Dosing must be individualized based on pain severity, prior analgesic treatment, and patient-specific risk factors. Physicians aim to prescribe the lowest effective dose for the shortest duration.
- Daily Limits: Because each tablet contains 325 mg of acetaminophen, the total daily intake of acetaminophen from all sources (prescription and over-the-counter) must not exceed 4,000 mg per 24 hours (many guidelines recommend keeping intake below 3,000 mg/day) to prevent acute liver toxicity.
- Administration: Can be taken with or without food. Taking it with meals or milk may reduce opioid-induced gastrointestinal upset.
Side Effects
Common Side Effects
- Gastrointestinal: Nausea, vomiting, constipation, dry mouth, abdominal discomfort.
- Neurological & CNS: Drowsiness, dizziness, sedation, lightheadedness, headache.
- Dermatological: Mild pruritus (itching) or sweating.
Severe & Life-Threatening Side Effects
- Respiratory Depression: Abnormally slow, shallow, or irregular breathing.
- Severe Hypotension: Significant drops in blood pressure, orthostasis, or syncope.
- Hepatotoxicity: Liver injury caused by excess acetaminophen (signs include jaundice, dark urine, upper right quadrant pain).
- Anaphylaxis & Severe Cutaneous Reactions: Urticaria, swelling of the face/tongue, Stevens-Johnson Syndrome (SJS), or Toxic Epidermal Necrolysis (TEN).
- Adrenal Insufficiency: Fatigue, weakness, dizziness, and low blood pressure after prolonged opioid use.
Precautions & Drug Interactions
- CNS Depressants: Combining this medication with alcohol, benzodiazepines, barbiturates, muscle relaxants, or other sedatives exponentially increases the risk of severe sedation, coma, and fatal respiratory arrest.
- CYP3A4 & CYP2D6 Inhibitors/Inducers: Hydrocodone is metabolized primarily via the hepatic CYP450 enzyme system (specifically CYP3A4 and CYP2D6). Concomitant use with strong inhibitors (e.g., ketoconazole, erythromycin, ritonavir) can cause dangerously high hydrocodone plasma levels.
- Serotonergic Drugs: Co-administration with SSRIs, SNRIs, tricyclic antidepressants, or MAO inhibitors increases the risk of Serotonin Syndrome, a potentially life-threatening condition.
- Pre-existing Conditions: Use with caution in patients with hepatic impairment, renal dysfunction, respiratory conditions (COPD, asthma, sleep apnea), head trauma, increased intracranial pressure, or biliary tract dysfunction.
Black Box Warnings
The FDA requires boxed warnings for all hydrocodone/acetaminophen combination products due to critical safety risks:
- Addiction, Abuse, and Misuse: Opioid analgesics expose users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or dosage increases.
- Accidental Ingestion: Accidental ingestion of even a single dose, particularly by children, can result in a fatal opioid overdose.
- Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can cause life-threatening withdrawal in the newborn.
- Hepatotoxicity (Acetaminophen): Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant or death, primarily linked to overdosing or combining with alcohol.
- Concomitant Use with Benzodiazepines or CNS Depressants: Profound sedation, respiratory depression, coma, and death may result from concurrent use.